Company Performance Metrics
- Christophe Muller: Chief of External R&D and Partnering
- Greg Carven: Partner (Biologics)
Curie.Bio is a new VC model created to discover and develop important new medicines. We do that by investing directly into existing companies, creating focused spinouts, and helping founders build companies from scratch. We operate globally, and we manage two funds: the Seed Fund and the Breakout Fund. The Seed Fund focuses on advancing therapies
through preclinical milestones, such as achieving in vivo proof-of-concept or selecting a development candidate. The Breakout Fund focuses on advancing medicines through clinical trials to generate impactful human activity data.
- Our 85-person team of proven drug hunters and drug makers provides daily support to our portfolio companies and offers in-depth feedback on every new opportunity. We do real work.
- We now have ~$1.25 billion to fund transformative therapeutic ideas and recruit the best people.
- We’ve vetted 500 CROs and set up contracts with more than 100 to enable rapid and flexible project support. This network gives our portfolio companies access to cutting-edge discovery technologies and top-performing R&D teams globally, allowing for faster execution of the R&D plan with significant cost savings.
- We’ve seeded over 30 companies covering all major therapeutic areas, modalities, geographies, and founder backgrounds.
